<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="480">
  <stage>Registered</stage>
  <submitdate>9/09/2005</submitdate>
  <approvaldate>14/09/2005</approvaldate>
  <actrnumber>ACTRN12605000390684</actrnumber>
  <trial_identification>
    <studytitle>A phase II trial of weekly docetaxel (Taxotere) for patients with relapsed ovarian cancer who have previously received paclitaxel</studytitle>
    <scientifictitle>A phase II trial of weekly docetaxel (Taxotere) for patients with relapsed ovarian cancer who have previously received paclitaxel</scientifictitle>
    <utrn />
    <trialacronym>ANZGOG 02-01</trialacronym>
    <secondaryid>Australia and New Zealand Gynecological Oncology Group: ANZGOG 02-01</secondaryid>
    <secondaryid>National Clinical Trials Registry: NCTR575</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Relapsed ovarian cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Ovarian and primary peritoneal</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>4 cycles of docetaxel where a cycle is once a week for 5 weeks followed by a rest week.</interventions>
    <comparator />
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Tumour response</outcome>
      <timepoint>Assessed every 6 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to progression</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Toxicity</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>* Histologically proven epithelial carcinoma of the ovary, primary peritoneal carcinoma or fallopian tube carcinoma. * Patients must have previously received paclitaxel, and relapsed or progressed after cessation of paclitaxel. * Patients must have been treated previously with at least one platinum-containing chemotherapy regimen (platinum refers to either carboplatin or cisplatin). * Patients must have disease that is unidimensionally measurable or be suitable for assessment of CA125 response.  Patients without measurable disease who are to be followed by CA125 must have a CA125 &gt; 70 U/ml. * Patients may or may not have received hormonal therapy, immunotherapy or localized radiation therapy (previous radiotherapy exposure should not compromise the evaluation of the measurable/evaluable disease sites).  Patients must have been off all previous non-cytotoxic therapy for at least four weeks before study entry and must have recovered from the effects of prior therapy.  For patients on hormonal therapy who have clear evidence of progression on this treatment, a 2-week interval will be acceptable.  Prior radiotherapy should have involved &lt; 25% of bone marrow. * No prior chemotherapy/investigational drug therapy in the 4 weeks preceding study entry.  In case of previous treatment with mitomycin-C, high-dose carboplatin (dose &gt; 600mg/m2 or &gt; AUC 7) or nitrosoureas, a 6-week interval will be required. * WHO performance status 0-2. * Non-pregnant, non-lactating female patients.  Patients of childbearing potential must implement adequate contraceptive measures during study participation. * Age &gt; 18 years. * Life expectancy greater than or equal to 12 weeks. * Adequate haematological, renal and hepatic functions as defined by: (i) Haematology: - Neutrophils &gt; 1.5 x 109/l- Platelets &gt; 100 x 109/l. (ii) Hepatic function:- Total bilirubin &lt; upper-normal limit (UNL). - AST and ALT &lt; 2.5 x UNL. - ALP &lt; 5 x UNL (unless patient has bone metastases without any malignant or non-malignant liver disease). - Patients with AST and /or ALT &gt; 1.5 x UNL associated with ALP &gt; 2.5 x UNL are not eligible for the study. (iii) Renal function: - Creatinine &lt; 1.5 x UNL. * Patient's written informed consent must be obtained before any study specific screening procedures are performed, and in accordance to the local Ethics Committee requirements. * Patients must be accessible for treatment and follow-up.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>No exclusion criteria</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>16/10/2003</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>NHMRC Clinical Trial Centre c/- Univ of Sydney</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Aventis</fundingname>
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>N/A</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Border Medical Oncology</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Burnside Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Cabrini Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Canberra Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Christchurch Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Geelong Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Liverpool Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Mercy Hospital for Women</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Newcastle Mater Miersicordiae Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Prince of Wales Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Adelaide Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Brisbane Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Prince Alfred Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Women's Hospital, Melbourne</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Sir Charles Gairdner Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Danny Rischin</name>
      <address>Department of Gynaecological Oncology
Mercy Hospital for Women
7th Floor
126 Clarendon St
East Melbourne VIC 3002</address>
      <phone>+61 3 96561804</phone>
      <fax>+61 3 96561408</fax>
      <email>danny.rischin@petermac.org</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Kathleen Scott</name>
      <address>National Health and Medical Research Council (NHMRC) Clinical Trials Centre
Locked Bag 77
Camperdown NSW 1450</address>
      <phone>+61 2 95625069</phone>
      <fax>+61 2 95625094</fax>
      <email>kscott@ctc.usyd.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>